Insys Therapeutics Reports Second Quarter 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Insys Therapeutics (INSY) Misses Q2 EPS by 10c; DEA Quota Granted
August 6, 2015 6:52 AM EDTInsys Therapeutics (NASDAQ: INSY) reported Q2 EPS of $0.10, $0.10 worse than the analyst estimate of $0.20. Revenue for the quarter came in at $77.6 million versus the consensus estimate of $74.06 million.
DEA Quota Granted
On August 5, 2015, Insys received a DEA Quota of 200 kg for the... More
